

VALUE OF DATA

What could you do with, patient consented, regulatory-grade, real-world patient data?

The national oncology database brings unprecedented value to all stakeholders in cancer care.

It's about time.

FOR MORE INFORMATION CONTACT US

801-396-5190 | info@taprootco.com | taprootco.com



PATIENTS & PHYSICIANS

The reality: Novel tests and therapies are only available through cumbersome processes.

What we deliver: By providing a single, comprehensive database—accessible by all industry stakeholders—we can accelerate adoption of new tests and novel cancer therapies.

LABS & EQUIPMENT MANUFACTURERS

The reality: To obtain coverage, they need evidence of clinical value.

What we deliver: A database that matches diagnostic data, treatment details, and outcomes provides the necessary evidence to prove that a new test is clinically valuable, biologically sound, and scientifically validated.

DATA TECHNOLOGY COMPANIES

The reality: Most companies are using synthetic data, which generates poor results.

What we deliver: Standardized, high-quality and real (not synthetic) patient clinical data can help companies generate meaningful information and move medicine forward through predictive outcomes and new models for drug discovery.

PHARMACEUTICAL COMPANIES

The reality: Faster identification of patients for clinical trials can shorten drug development and time-to-market—resulting in efficiency and value.

What we deliver: Once drugs are ready for testing, companies can use our network and database to find the exact patients to populate clinical trials. Depending on the rarity of the cancer, this could shave years off the selection process.

RESEARCHERS

The reality: Researchers need better access to patients with specific cancer data, including pathology, staging, biomarkers, genomic sequencing, radiology and treatment.

What we deliver: Research-quality data that meets rigorous scientific standards can help researchers conduct complex studies, publish in shorter time frames and strengthen their opportunities for grant funding.

INVESTORS

The reality: By aligning with Taproot Health, investors become catalysts for a new era in precision oncology—moving the world toward personalized care.

What we deliver: By providing a one-stop resource for data—plus a unique revenue-sharing model that motivates physician participation—Taproot Health is disrupting traditional data models, challenging the status quo and setting a new standard with a next generation of data-as-a-service (DaaS) model.

Real Time Data at Point of Care.

NOVEL CLINICAL TRIAL

Driving value through scientifically, rigorous data aggregation.

PATIENT REPORTED **OUTCOMES**

Aggregating patient reported responses.

- Patient experience
- Quality of life



BIOMARKER

biomarker tested.

Higher numbers of detailed

information on patients being

DATA

• DNA • RNA • PROTEIN

TREATMENT DATA

Tracking all treatment regimens with dates and doses.

- Chemotherapy
- Targeted Therapy
- Immuno-Oncology



MEDICAL DECISIONS

Recording reason of treatment changes.

CLINICAL REPORTS

Maintaining clinical reports

as part of patient records.

• Pathology

Radiology

- Adverse event
- Treatment completion



IMAGING

Linking imaging to clinical outcomes.

• PET, CT, MRI



PATIENT RESPONSE

Physician certified.

 Independently verifiable



CLINICAL

Matching biomarker testing to clinical outcomes.

- Patient consent
- Overall survival



OUTCOME

